Cargando…
Rhabdomyolysis due to warfarin and atorvastatin combination therapy in a patient with ischemic heart disease: (A drug interaction)
INTRODUCTION: Although atorvastatin has serious adverse effects, including hepatotoxicity and myopathy, it can cause drug interactions and side effects such as rhabdomyolysis and acute kidney injury, especially when combined with warfarin, which uses the same enzyme pathway for metabolism. CASE PRES...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8861410/ https://www.ncbi.nlm.nih.gov/pubmed/35242328 http://dx.doi.org/10.1016/j.amsu.2022.103384 |
_version_ | 1784654879485067264 |
---|---|
author | Soliemanabad, Saeed Kargar Rasouli, Kimia Zakariaei, Zakaria Soleymani, Mostafa Aliabadi, Parastoo Karimi |
author_facet | Soliemanabad, Saeed Kargar Rasouli, Kimia Zakariaei, Zakaria Soleymani, Mostafa Aliabadi, Parastoo Karimi |
author_sort | Soliemanabad, Saeed Kargar |
collection | PubMed |
description | INTRODUCTION: Although atorvastatin has serious adverse effects, including hepatotoxicity and myopathy, it can cause drug interactions and side effects such as rhabdomyolysis and acute kidney injury, especially when combined with warfarin, which uses the same enzyme pathway for metabolism. CASE PRESENTATION: We describe a 66-year-old man with a history of ischemic heart disease who developed renal complications and rhabdomyolysis after concomitant use of atorvastatin and warfarin. DISCUSSION: Statins reduce serum LDL cholesterol levels significantly. It is a safe and cost-effective medicine used in the treatment of DLP as well as the primary and secondary prevention of CAD, atherosclerosis, myocardial infarction, and stroke. Despite their benefits, statins can cause side effects in various organs of the body, including the gastrointestinal tract, CNS, liver, and kidneys. CONCLUSION: Statins are widely prescribed to patients with cardiovascular problems. Therefore, clinicians should pay attention to the patient's medical history, current prescribed doses, and drug interactions when adding new drugs or adjusting existing drugs. |
format | Online Article Text |
id | pubmed-8861410 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Elsevier |
record_format | MEDLINE/PubMed |
spelling | pubmed-88614102022-03-02 Rhabdomyolysis due to warfarin and atorvastatin combination therapy in a patient with ischemic heart disease: (A drug interaction) Soliemanabad, Saeed Kargar Rasouli, Kimia Zakariaei, Zakaria Soleymani, Mostafa Aliabadi, Parastoo Karimi Ann Med Surg (Lond) Case Report INTRODUCTION: Although atorvastatin has serious adverse effects, including hepatotoxicity and myopathy, it can cause drug interactions and side effects such as rhabdomyolysis and acute kidney injury, especially when combined with warfarin, which uses the same enzyme pathway for metabolism. CASE PRESENTATION: We describe a 66-year-old man with a history of ischemic heart disease who developed renal complications and rhabdomyolysis after concomitant use of atorvastatin and warfarin. DISCUSSION: Statins reduce serum LDL cholesterol levels significantly. It is a safe and cost-effective medicine used in the treatment of DLP as well as the primary and secondary prevention of CAD, atherosclerosis, myocardial infarction, and stroke. Despite their benefits, statins can cause side effects in various organs of the body, including the gastrointestinal tract, CNS, liver, and kidneys. CONCLUSION: Statins are widely prescribed to patients with cardiovascular problems. Therefore, clinicians should pay attention to the patient's medical history, current prescribed doses, and drug interactions when adding new drugs or adjusting existing drugs. Elsevier 2022-02-12 /pmc/articles/PMC8861410/ /pubmed/35242328 http://dx.doi.org/10.1016/j.amsu.2022.103384 Text en © 2022 The Authors https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/). |
spellingShingle | Case Report Soliemanabad, Saeed Kargar Rasouli, Kimia Zakariaei, Zakaria Soleymani, Mostafa Aliabadi, Parastoo Karimi Rhabdomyolysis due to warfarin and atorvastatin combination therapy in a patient with ischemic heart disease: (A drug interaction) |
title | Rhabdomyolysis due to warfarin and atorvastatin combination therapy in a patient with ischemic heart disease: (A drug interaction) |
title_full | Rhabdomyolysis due to warfarin and atorvastatin combination therapy in a patient with ischemic heart disease: (A drug interaction) |
title_fullStr | Rhabdomyolysis due to warfarin and atorvastatin combination therapy in a patient with ischemic heart disease: (A drug interaction) |
title_full_unstemmed | Rhabdomyolysis due to warfarin and atorvastatin combination therapy in a patient with ischemic heart disease: (A drug interaction) |
title_short | Rhabdomyolysis due to warfarin and atorvastatin combination therapy in a patient with ischemic heart disease: (A drug interaction) |
title_sort | rhabdomyolysis due to warfarin and atorvastatin combination therapy in a patient with ischemic heart disease: (a drug interaction) |
topic | Case Report |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8861410/ https://www.ncbi.nlm.nih.gov/pubmed/35242328 http://dx.doi.org/10.1016/j.amsu.2022.103384 |
work_keys_str_mv | AT soliemanabadsaeedkargar rhabdomyolysisduetowarfarinandatorvastatincombinationtherapyinapatientwithischemicheartdiseaseadruginteraction AT rasoulikimia rhabdomyolysisduetowarfarinandatorvastatincombinationtherapyinapatientwithischemicheartdiseaseadruginteraction AT zakariaeizakaria rhabdomyolysisduetowarfarinandatorvastatincombinationtherapyinapatientwithischemicheartdiseaseadruginteraction AT soleymanimostafa rhabdomyolysisduetowarfarinandatorvastatincombinationtherapyinapatientwithischemicheartdiseaseadruginteraction AT aliabadiparastookarimi rhabdomyolysisduetowarfarinandatorvastatincombinationtherapyinapatientwithischemicheartdiseaseadruginteraction |